{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T20:55:31Z","timestamp":1794603331823,"version":"4.9.1"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T00:00:00Z","timestamp":1756080000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T00:00:00Z","timestamp":1756080000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82270177"],"award-info":[{"award-number":["82270177"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82100247"],"award-info":[{"award-number":["82100247"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018904","name":"Beijing Xisike Clinical Oncology Research Foundation","doi-asserted-by":"publisher","award":["Y-2022YMJN\/MS-0005"],"award-info":[{"award-number":["Y-2022YMJN\/MS-0005"]}],"id":[{"id":"10.13039\/100018904","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Exp Hematol Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Chimeric antigen receptor (CAR)-T-cell therapy has achieved remarkable clinical success in the treatment of B-cell malignancies; however, its efficacy can be limited by poor T-cell persistence and insufficient antitumor activity in certain cases. Moreover, interleukin-12 (IL-12) is a prominent agent in cancer immunotherapy, but its clinical application is constrained by severe toxicity associated with systemic exposure. In this study, we developed a novel cytokine delivery platform based on CAR target-modified cell-derived extracellular vesicles (EVs) that preferentially bind CAR-T cells to improve CAR-T-cell function. EVs with surface-displayed CD19 and\/or IL-12 were successfully generated from HEK-293T cells. Compared with an equivalent concentration of rhIL-12, IL-12 EVs significantly enhanced the effector function of anti-CD19 CAR-T cells in vitro, resulting in increased Interferon-\u03b3 (IFN-\u03b3) and TNF-\u03b1 secretion, cytolytic activity, and T-cell expansion. Additionally, compared with EVs expressing IL-12 alone, EVs co-expressing IL-12 and CD19 (CD19\/IL-12 EVs) exhibited superior binding efficiency to CAR-T cells but not to T cells, as indicated by flow cytometry. In xenograft model mice bearing CD19\u2009+\u2009Raji tumors, intratumoral injection of CD19\/IL-12 EVs resulted in durable antitumor responses and enhanced the in vivo expansion of CAR-T cells, outperforming CD19 EVs, IL-12 EVs and control EVs, without causing systemic toxicity. RNA sequencing (RNA-seq) analysis of CAR-T cells stimulated with EVs suggested that the increased efficacy was driven by IL-12 signaling. These data demonstrate that CAR-targeted modified EVs may serve as targeted cytokine delivery systems for CAR-T cells, offering a safe and effective strategy to augment CAR-T-cell function.<\/jats:p>","DOI":"10.1186\/s40164-025-00701-z","type":"journal-article","created":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T11:53:18Z","timestamp":1756122798000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Improving CAR-T cell function through a targeted cytokine delivery system utilizing car target-modified extracellular vesicles"],"prefix":"10.1186","volume":"14","author":[{"given":"Yuanyuan","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meijuan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shujia","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianjiao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanwei","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhang","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liting","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueyan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kefeng","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tongjuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dengju","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Mu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jue","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,25]]},"reference":[{"key":"701_CR1","doi-asserted-by":"crossref","unstructured":"Houot R, Bachy E, Cartron G et al. Axicabtagene Ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trial[J]. Nat Med 2023;29(10):2593\u2013601.","DOI":"10.1038\/s41591-023-02572-5"},{"key":"701_CR2","doi-asserted-by":"crossref","unstructured":"Shalabi H, Qin H. Su A, CD19\/22 CAR T cells in children and young adults with B-ALL: phase 1 results and development of a novel bicistronic CAR[J].Blood, 2022;140(5):451\u201363.","DOI":"10.1182\/blood.2022015795"},{"key":"701_CR3","doi-asserted-by":"crossref","unstructured":"Fraietta JA, Lacey S F, Orlando E J et al. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia[J]. Nat Med. 2018;24(5):563\u201371.","DOI":"10.1038\/s41591-018-0010-1"},{"key":"701_CR4","doi-asserted-by":"crossref","unstructured":"Walker A J, Majzner R G, Zhang L et al. Tumor antigen and receptor densities regulate efficacy of a chimeric antigen receptor targeting anaplastic lymphoma Kinase[J].Mol ther, 2017;25(9):2189\u2013201.","DOI":"10.1016\/j.ymthe.2017.06.008"},{"key":"701_CR5","doi-asserted-by":"crossref","unstructured":"Gumber D, Wang L D.Improving. CAR-T immunotherapy: Overcoming the challenges of T cell exhaustion[J].EBioMedicine, 2022;77:103941.","DOI":"10.1016\/j.ebiom.2022.103941"},{"key":"701_CR6","doi-asserted-by":"crossref","unstructured":"Arany Z Bakerdj, Baur J A et al. CAR T therapy beyond cancer: the evolution of a living drug[J].Nature, 2023;619(7971):707\u201315.","DOI":"10.1038\/s41586-023-06243-w"},{"issue":"9","key":"701_CR7","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.1038\/s41591-022-01916-x","volume":"28","author":"N SCHOLLER","year":"2022","unstructured":"Scholler N, Perbost R, Locke F L, et al. Tumor immune contexture is a determinant of anti-CD19 CAR T cell efficacy in large B cell lymphoma[J]. Nat Med. 2022;28(9):1872\u201382.","journal-title":"Nat Med"},{"key":"701_CR8","doi-asserted-by":"crossref","unstructured":"Abbott R C, Hughes-Parry H E. Jenkins M r.to go or not to go? Biological logic gating engineered T cells[J].J Immunother Cancer,2022;10(4).","DOI":"10.1136\/jitc-2021-004185"},{"issue":"12","key":"701_CR9","doi-asserted-by":"publisher","first-page":"4746","DOI":"10.1172\/JCI58814","volume":"121","author":"P KERKAR S P, GOLDSZMID R S, MURANSKI","year":"2011","unstructured":"Kerkar S P, Goldszmid R S, Muranski P, et al. IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors[J]. J Clin Invest. 2011;121(12):4746\u201357.","journal-title":"J Clin Invest"},{"key":"701_CR10","doi-asserted-by":"crossref","unstructured":"Gao W, Pan J. Pan J.Antitumor Activities of Interleukin-12 in Melanoma[J].Cancers (Basel),2022;14(22).","DOI":"10.3390\/cancers14225592"},{"issue":"8","key":"701_CR11","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1038\/ni.2366","volume":"13","author":"VIGNALI D A","year":"2012","unstructured":"Vignali D A. Kuchroo V K.IL-12 family cytokines: immunological playmakers[J]. Nat Immunol. 2012;13(8):722\u20138.","journal-title":"Nat Immunol"},{"key":"701_CR12","doi-asserted-by":"crossref","unstructured":"Zimmermann K, Kuehle J, Dragon A C et al. Design and characterization of an All-in-One lentiviral vector system combining constitutive Anti-G(D2) CAR expression and inducible Cytokines[J].Cancers (Basel), 2020;12(2).","DOI":"10.3390\/cancers12020375"},{"issue":"5","key":"701_CR13","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1016\/j.ymthe.2020.02.016","volume":"28","author":"Y PORTER C E, ROSEWELL SHAW A, JUNG","year":"2020","unstructured":"Porter C E, Rosewell Shaw A, Jung Y, et al. Oncolytic adenovirus armed with bite, cytokine, and checkpoint inhibitor enables CAR T cells to control the growth of heterogeneous. Tumors[J] Mol Ther. 2020;28(5):1251\u201362.","journal-title":"Tumors[J] Mol Ther"},{"key":"701_CR14","doi-asserted-by":"crossref","unstructured":"Luo Y, Chen Z. Sun M, IL-12 nanochaperone-engineered CAR T cell for robust tumor-immunotherapy[J].Biomaterials, 2022;281:121341.","DOI":"10.1016\/j.biomaterials.2021.121341"},{"issue":"2","key":"701_CR15","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/j.ymthe.2021.10.011","volume":"30","author":"A HOMBACH","year":"2022","unstructured":"Hombach A, Barden M. IL12 integrated into the CAR exodomain converts CD8(+) T cells to poly-functional NK-like cells with superior killing of antigen-loss tumors[J]. Mol Ther. 2022;30(2):593\u2013605.","journal-title":"Mol Ther"},{"key":"701_CR16","doi-asserted-by":"crossref","unstructured":"Smole A, Benton A, Poussin M A et al. Expression of inducible factors reprograms CAR-T cells for enhanced function and safety[J]. Cancer Cell 2022;40(12):1470\u2013e14871477.","DOI":"10.1016\/j.ccell.2022.11.006"},{"key":"701_CR17","first-page":"3285","volume":"18","author":"Y ZHANG","year":"2023","unstructured":"Zhang Y, Dou Y, Liu Y, et al. Adv Therapeutic Appl Extracell Vesicles[J] Int J Nanomed. 2023;18:3285\u2013307.","journal-title":"Adv Therapeutic Appl Extracell Vesicles[J] Int J Nanomed"},{"key":"701_CR18","doi-asserted-by":"crossref","unstructured":"Karpman D, St\u00e5hl AL. Arvidsson i.extracellular vesicles in renal disease[J]. Nat Rev Nephrol 2017;13(9):545\u201362.","DOI":"10.1038\/nrneph.2017.98"},{"key":"701_CR19","doi-asserted-by":"publisher","first-page":"30087","DOI":"10.3402\/jev.v4.30087","volume":"4","author":"T LENER","year":"2015","unstructured":"Lener T, Gimona M. Applying extracellular vesicles based therapeutics in clinical trials - an ISEV position paper[J]. J Extracell Vesicles. 2015;4:30087.","journal-title":"J Extracell Vesicles"},{"key":"701_CR20","doi-asserted-by":"crossref","unstructured":"Tang T T, Wang B, Wu M et al. Extracellular vesicle-encapsulated IL-10 as novel nanotherapeutics against ischemic AKI[J].Sci adv, 2020;6(33):eaaz0748.","DOI":"10.1126\/sciadv.aaz0748"},{"issue":"3","key":"701_CR21","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1158\/1535-7163.MCT-20-0484","volume":"20","author":"ND LEWIS","year":"2021","unstructured":"Lewis ND, Sia C L, Kirwin K, et al. Exosome surface display of IL12 results in Tumor-Retained Pharmacology with superior potency and limited systemic exposure compared with Recombinant IL12[J]. Mol Cancer Ther. 2021;20(3):523\u201334.","journal-title":"Mol Cancer Ther"},{"key":"701_CR22","doi-asserted-by":"crossref","unstructured":"Dooley K, Mcconnell R E, XU K et al. A versatile platform for generating engineered extracellular vesicles with defined therapeutic properties[J]. Mol Ther 2021;29(5):1729\u201343.","DOI":"10.1016\/j.ymthe.2021.01.020"},{"key":"701_CR23","doi-asserted-by":"crossref","unstructured":"Casella G, Rasouli J. Boehm A, Oligodendrocyte-derived extracellular vesicles as antigen-specific therapy for autoimmune neuroinflammation in mice[J].Sci Transl Med, 2020;12(568).","DOI":"10.1126\/scitranslmed.aba0599"},{"key":"701_CR24","doi-asserted-by":"crossref","unstructured":"Ukrainskaya V, Rubtsov Y. Pershin D, Antigen-Specific stimulation and expansion of CAR-T cells using membrane vesicles as. Target Cell Surrogates[J] Small 2021;17(45):e2102643.","DOI":"10.1002\/smll.202102643"},{"key":"701_CR25","doi-asserted-by":"crossref","unstructured":"Cox MJ, Lucien F, Sakemura R et al. Leukemic extracellular vesicles induce chimeric antigen receptor T cell dysfunction in chronic lymphocytic leukemia[J]. Mol Ther 2021;29(4):1529\u201340.","DOI":"10.1016\/j.ymthe.2020.12.033"},{"key":"701_CR26","doi-asserted-by":"publisher","first-page":"49","DOI":"10.2147\/IJN.S390720","volume":"18","author":"Y ZHANG","year":"2023","unstructured":"Zhang Y, GE T, Huang M, et al. Extracellular vesicles expressing CD19 antigen improve expansion and efficacy of CD19-Targeted CAR-T Cells[J]. Int J Nanomed. 2023;18:49\u201363.","journal-title":"Int J Nanomed"},{"key":"701_CR27","unstructured":"Leonard J P, Sherman M L, Fisher GL et al. Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production[J].Blood,1997;90(7):2541\u20138."},{"key":"701_CR28","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.jconrel.2020.07.033","volume":"326","author":"Q XU","year":"2020","unstructured":"Xu Q, Zhang Z. Tropism-facilitated delivery of CRISPR\/Cas9 system with chimeric antigen receptor-extracellular vesicles against B-cell malignancies[J]. J Control Release. 2020;326:455\u201367.","journal-title":"J Control Release"},{"key":"701_CR29","doi-asserted-by":"crossref","unstructured":"Silva D A, Yu S, Ulge U Y et al. De Novo design of potent and selective mimics of IL-2 and IL-15[J].Nature,2019;565(7738):186\u201391.","DOI":"10.1038\/s41586-018-0830-7"},{"key":"701_CR30","doi-asserted-by":"crossref","unstructured":"Adachi K, Kano Y, Nagai T et al. IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor[J].Nat biotechnol,2018;36(4):346\u201351.","DOI":"10.1038\/nbt.4086"},{"issue":"48","key":"701_CR31","first-page":"E7788","volume":"113","author":"HURTONLV SINGH","year":"2016","unstructured":"Singh Hurtonlv, Najjar A M H, et al. Tethered IL-15 augments antitumor activity and promotes a stem-cell memory subset in tumor-specific T cells[J]. Proc Natl Acad Sci U S A. 2016;113(48):E7788\u201397.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"701_CR32","doi-asserted-by":"crossref","unstructured":"Bhatia, V, Kamat N V, Pariva T E et al. Targeting advanced prostate cancer with STEAP1 chimeric antigen receptor T cell and tumor-localized IL-12 immunotherapy[J].Nat Commun,2023;14(1):2041.","DOI":"10.1038\/s41467-023-37874-2"},{"issue":"1","key":"701_CR33","doi-asserted-by":"publisher","first-page":"5100","DOI":"10.1038\/s41467-019-13088-3","volume":"10","author":"M SACHDEVA","year":"2019","unstructured":"Sachdeva M, Busser B W Temburnis, et al. Repurposing endogenous immune pathways to tailor and control chimeric antigen receptor T cell functionality[J]. Nat Commun. 2019;10(1):5100.","journal-title":"Nat Commun"},{"key":"701_CR34","doi-asserted-by":"crossref","unstructured":"Mckenna M K, Englisch A, Brenner B et al. Mesenchymal stromal cell delivery of oncolytic immunotherapy improves CAR-T cell antitumor activity[J]. Mol Ther 2021;29(5):1808\u201320.","DOI":"10.1016\/j.ymthe.2021.02.004"},{"issue":"3","key":"701_CR35","doi-asserted-by":"publisher","first-page":"100978","DOI":"10.1016\/j.xcrm.2023.100978","volume":"4","author":"I OLIVERA","year":"2023","unstructured":"Olivera I, Bola\u00f1os E, Gonzalez-Gomariz J, et al. mRNAs encoding IL-12 and a decoy-resistant variant of IL-18 synergize to engineer T cells for efficacious intratumoral adoptive immunotherapy[J]. Cell Rep Med. 2023;4(3):100978.","journal-title":"Cell Rep Med"},{"issue":"1","key":"701_CR36","doi-asserted-by":"publisher","first-page":"4737","DOI":"10.1038\/s41467-023-40115-1","volume":"14","author":"CHRISTIANL LEE E H J, MURAD J P","year":"2023","unstructured":"Lee E H J, Murad J P Christianl, et al. Antigen-dependent IL-12 signaling in CAR T cells promotes regional to systemic disease targeting[J]. Nat Commun. 2023;14(1):4737.","journal-title":"Nat Commun"},{"issue":"1","key":"701_CR37","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/d41573-020-00220-y","volume":"20","author":"CULLY M","year":"2021","unstructured":"Cully M. Exosome-based candidates move into the clinic[J]. Nat Rev Drug Discov. 2021;20(1):6\u20137.","journal-title":"Nat Rev Drug Discov"},{"key":"701_CR38","doi-asserted-by":"publisher","first-page":"31053","DOI":"10.3402\/jev.v5.31053","volume":"5","author":"KOOIJMANS S A","year":"2016","unstructured":"Kooijmans S A, Aleza C G, Roffler S R, et al. Display of GPI-anchored anti-EGFR nanobodies on extracellular vesicles promotes tumour cell targeting[J]. J Extracell Vesicles. 2016;5:31053.","journal-title":"J Extracell Vesicles"},{"key":"701_CR39","doi-asserted-by":"crossref","unstructured":"Kofoed C, Erkalo G, Tay N E S et al. Programmable protein ligation on cell surfaces[J].Nature, 2025.","DOI":"10.1038\/s41586-025-09287-2"},{"key":"701_CR40","doi-asserted-by":"crossref","unstructured":"Rosewell Shaw A, Porter C E, Watanabe N et al. Adenovirotherapy delivering cytokine and checkpoint inhibitor augments CAR T cells against metastatic head and neck Cancer[J].Mol ther, 2017;25(11):2440\u201351.","DOI":"10.1016\/j.ymthe.2017.09.010"},{"key":"701_CR41","doi-asserted-by":"crossref","unstructured":"Kerkar SP, Muranski P. Kaiser A, Tumor-specific CD8\u2009+\u2009T cells expressing interleukin-12 eradicate established cancers in lymphodepleted hosts[J]. Cancer Res 2010;70(17):6725\u201334.","DOI":"10.1158\/0008-5472.CAN-10-0735"},{"issue":"10","key":"701_CR42","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.1158\/1078-0432.CCR-14-2085","volume":"21","author":"L ZHANG","year":"2015","unstructured":"Zhang L, Morgan R A, Beane JD, et al. Tumor-infiltrating lymphocytes genetically engineered with an inducible gene encoding interleukin-12 for the immunotherapy of metastatic melanoma[J]. Clin Cancer Res. 2015;21(10):2278\u201388.","journal-title":"Clin Cancer Res"},{"issue":"67","key":"701_CR43","doi-asserted-by":"publisher","first-page":"eabi6899","DOI":"10.1126\/sciimmunol.abi6899","volume":"7","author":"D XUE","year":"2022","unstructured":"Xue D, Moon B, Liao J, et al. A tumor-specific pro-IL-12 activates preexisting cytotoxic T cells to control established tumors[J]. Sci Immunol. 2022;7(67):eabi6899.","journal-title":"Sci Immunol"},{"issue":"1","key":"701_CR44","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/s12951-022-01330-y","volume":"20","author":"J CHEN","year":"2022","unstructured":"Chen J, Tan Q, Yang Z, et al. Engineered extracellular vesicles: potentials in cancer combination therapy[J]. J Nanobiotechnol. 2022;20(1):132.","journal-title":"J Nanobiotechnol"},{"key":"701_CR45","doi-asserted-by":"crossref","unstructured":"Nguyen K G, Vrabel M R, Mantooth S M et al. Localized Interleukin-12 for cancer Immunotherapy[J].Front Immunol, 2020;11:575597.","DOI":"10.3389\/fimmu.2020.575597"},{"key":"701_CR46","doi-asserted-by":"crossref","unstructured":"Von Lersner A K, Fernandes F, Ozawa P M, M et al. Multiparametric Single-Vesicle flow cytometry resolves extracellular vesicle heterogeneity and reveals selective regulation of biogenesis and cargo Distribution[J].ACS nano, 2024;18(15):10464\u201384.","DOI":"10.1021\/acsnano.3c11561"},{"issue":"10","key":"701_CR47","doi-asserted-by":"publisher","first-page":"e12130","DOI":"10.1002\/jev2.12130","volume":"10","author":"E SILVA A M, L\u00e1ZARO-IB\u00e1\u00f1EZ","year":"2021","unstructured":"Silva A M, L\u00f1zaro-Ib\u00f1\u00f1ez E, Gunnarsson A, et al. Quantification of protein cargo loading into engineered extracellular vesicles at single-vesicle and single-molecule resolution[J]. J Extracell Vesicles. 2021;10(10):e12130.","journal-title":"J Extracell Vesicles"},{"key":"701_CR48","doi-asserted-by":"crossref","unstructured":"Lynn R C, Weber E W, Sotillo E et al. c-Jun overexpression in CAR T cells induces exhaustion resistance[J].Nature, 2019;576(7786):293\u2013300.","DOI":"10.1038\/s41586-019-1805-z"},{"key":"701_CR49","doi-asserted-by":"crossref","unstructured":"Wang N, Hu X. Cao W, Efficacy and safety of CAR19\/22 T-cell cocktail therapy in patients with refractory\/relapsed B-cell malignancies[J].Blood, 2020;135(1):17\u201327.","DOI":"10.1182\/blood.2019000017"},{"issue":"7","key":"701_CR50","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1007\/s00262-023-03418-2","volume":"72","author":"J JIN","year":"2023","unstructured":"Jin J, Liu T, Cheng J, et al. MIP3\u03b1 as an early prognostic predictor for patients with B-cell malignancies receiving CD19\/CD22-redirected CAR-T cell cocktail therapy[J]. Cancer Immunol Immunother. 2023;72(7):2245\u201356.","journal-title":"Cancer Immunol Immunother"},{"key":"701_CR51","doi-asserted-by":"crossref","unstructured":"Kutner R H, Zhang X Y Reiserj. Production, concentration and Titration of pseudotyped HIV-1-based lentiviral vectors[J]. Nat Protoc 2009;4(4):495\u2013505.","DOI":"10.1038\/nprot.2009.22"},{"issue":"6","key":"701_CR52","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1089\/104303403764539387","volume":"14","author":"G LIZ\u00e9E","year":"2003","unstructured":"Liz\u00f9e G, Aerts J L, Gonzales M I, et al. Real-time quantitative reverse transcriptase-polymerase chain reaction as a method for determining lentiviral vector titers and measuring transgene expression[J]. Hum Gene Ther. 2003;14(6):497\u2013507.","journal-title":"Hum Gene Ther"},{"key":"701_CR53","doi-asserted-by":"crossref","unstructured":"Lannigan J. Erdbruegger u.imaging flow cytometry for the characterization of extracellular vesicles[J].Methods, 2017;112:55\u201367.","DOI":"10.1016\/j.ymeth.2016.09.018"},{"issue":"1","key":"701_CR54","doi-asserted-by":"publisher","first-page":"1587567","DOI":"10.1080\/20013078.2019.1587567","volume":"8","author":"A G\u00f6RGENS","year":"2019","unstructured":"G\u00f6rgens A, Bremer M, Ferrer-Tur R, et al. Optimisation of imaging flow cytometry for the analysis of single extracellular vesicles by using fluorescence-tagged vesicles as biological reference material[J]. J Extracell Vesicles. 2019;8(1):1587567.","journal-title":"J Extracell Vesicles"},{"issue":"1","key":"701_CR55","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1186\/s11671-020-03399-6","volume":"15","author":"Y JURGIELEWICZ B J, YAO","year":"2020","unstructured":"Jurgielewicz B J, Yao Y, Stice SL. .Kinetics and specificity of HEK293T extracellular vesicle uptake using imaging flow Cytometry[J]. Nanoscale Res Lett. 2020;15(1):170.","journal-title":"Nanoscale Res Lett"},{"key":"701_CR56","doi-asserted-by":"crossref","unstructured":"Mchugh MD, Park J, Uhrich R et al. Paracrine co-delivery of TGF-\u03b2 and IL-2 using CD4-targeted nanoparticles for induction and maintenance of regulatory T cells[J].Biomaterials, 2015;59:172\u201381.","DOI":"10.1016\/j.biomaterials.2015.04.003"},{"key":"701_CR57","doi-asserted-by":"crossref","unstructured":"Doan A E, Mueller K P, Chen A Y et al. Foxo1 is a master regulator of memory programming in CAR T cells[J].Nature, 2024;629(8010):211\u20138.","DOI":"10.1038\/s41586-024-07300-8"},{"key":"701_CR58","doi-asserted-by":"crossref","unstructured":"Lou Y, Chen C, Long X et al. Detection and quantification of chimeric antigen receptor transgene copy number by droplet digital PCR versus Real-Time PCR[J].J mol diagn, 2020;22(5):699\u2013707.","DOI":"10.1016\/j.jmoldx.2020.02.007"}],"container-title":["Experimental Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40164-025-00701-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40164-025-00701-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40164-025-00701-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T14:37:26Z","timestamp":1757428646000},"score":1,"resource":{"primary":{"URL":"https:\/\/ehoonline.biomedcentral.com\/articles\/10.1186\/s40164-025-00701-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,25]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["701"],"URL":"https:\/\/doi.org\/10.1186\/s40164-025-00701-z","relation":{},"ISSN":["2162-3619"],"issn-type":[{"value":"2162-3619","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,25]]},"assertion":[{"value":"5 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval for the study was granted by the Ethics Committee of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China (decision 30 December 2020). The animal study was approved by the Ethics Committee of Tongji Medical College.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"110"}}